Cereno Scientific announces that equity research company Edison initiates coverage of the company
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that equity research company Edison Investment Research has been engaged by Cereno to produce regular, in-depth research on the company. The intention is to raise the visibility of the company and enable investors and stakeholders to develop an improved understanding of the business.
Edison's research is read on a free-to-access basis by individuals and institutions across the globe. Edison's coverage of Cereno will be available on the company website, www.cerenoscientific.com, as well as on Edison’s website, www.edisongroup.com.
“I firmly believe in the value that engaging a seasoned equity analyst brings to our shareholders. These professionals provide an essential bridge between our company's operations and the complex financial markets. Their expert analyses and deep understanding of market trends translate into clearer, more strategic investment insights for our shareholders. This collaboration is pivotal in aligning our company's growth trajectory with the expectations and interests of our shareholders, ensuring that every investment decision is made with precision, foresight, and a deep commitment to maximizing shareholder value,” said Sten R. Sörensen, CEO, Cereno Scientific.
For further information, please contact:
Tove Bergenholt, Director IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 732-366 246
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q2 2024. After requests by investigators in the Phase II study, a “compassionate use” application for CS1 is currently being pursued. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.